MedPath

P-cresol: Correlation With Glomerular Filtration Rate and Outcome in Chronic Kidney Disease

Completed
Conditions
Renal Progression
Risk Factors
Death
Interventions
Other: there are no interventions currently listed for this study
Registration Number
NCT00888030
Lead Sponsor
Chang Gung Memorial Hospital
Brief Summary

End-stage renal disease is a global epidemia with an estimated incidence of 7% per year and high morbidity-mortality rate. Early detection of chronic kidney disease (CKD) and intervention for CKD complication is important to retard renal progression. However, "traditional uremic toxin" or "small water-soluble molecules" are poorly correlated with the renal function, uremic symptoms and outcomes of CKD patients.

Putative protein-bound solute, p-cresol, is accumulated in ESRD patients receiving dialysis therapy. This uremic solute was associated with endothelial dysfunction, immune dysregulation and can predict outcome in hemodialysis patient. P-cresol inhibits endothelial cell proliferation and endothelial response to inflammatory cytokines. In vitro, p-cresol decreases leukocyte transendotherliar migratory function and inhibit production of phagocyte reactive species. Clinically, p-cresol plays a pathophysiological role in the uremic toxicity. High free serum level of p-cresol is associated with mortality in hemodialysis patients.

Information of p-cresol in CKD patients is not available. The investigators hypothesized p-cresol can be accumulated in early CKD and have a positive correlation with the morbidity- mortality of CKD patients.

Value of p-cresol in different stages of CRF is still unknown. Information of p-cresol in CKD patients is not available. The investigators hypothesized p-cresol can be accumulated in early CKD and have a positive correlation with the morbidity- mortality of CKD patients.

The principal aim of this prospective cohort study is to investigate the association between total serum levels of p-cresol and the glomerular filtration rate. The correlation of level of p-cresol and morbidity-mortality in CKD patients will be also evaluated.

To determine the relationship, patients of nephrology clinic with a diagnosis of CKD were enrolled in this prospective study and follow-up for 1-year period. The association between total and free serum levels of p-cresol and the glomerular filtration rate were evaluated in CKD patients. The p-cresol level was correlated with other many inflammatory markers (white blood cell counts, ferritin, hs-crp, leptin) and also with the hospitalization rate secondary to cardiovascular and infectious event. The renal outcome and all-cause mortality was assessed. Determination of this relationship can help to establish an accurate marker for early detection of CKD and also its prognostic role in CKD patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
300
Inclusion Criteria
  • All CKD patients attended at out-patient department of nephrology were included for analysis.
  • The inclusion criteria were adults aged > 18 y/o or < 80 y/o
  • Estimated GFR or CCR < 60 ml/min
  • No spontaneous renal improvement or progression in past 3 months.
Exclusion Criteria
  • Recent cardiovascular disease (Coronary artery disease, myocardial ischemia, cerebrovascular disease or peripheral artery disease) in past 3 months
  • Recent infections requiring admission in past 3 months
  • Uncontrolled hypertension
  • Serum albumin level < 2.5mg/dL
  • Unwilling to participate in the trial.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
2there are no interventions currently listed for this studyCKD patients with normal p-cresol
3there are no interventions currently listed for this studyCKD patient with normal indoxyl sulfate
4there are no interventions currently listed for this studyCKD patients with high indoxyl sulfate
1there are no interventions currently listed for this studyCKD patients with high p cresol
Primary Outcome Measures
NameTimeMethod
end stage renal disease, reduction of eGFR by 50% and death1 year
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Department of Nephrology,Chang Gung Memorial Hospital

🇨🇳

Keelung, Taiwan

© Copyright 2025. All Rights Reserved by MedPath